Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.
A targeted drug for a tricky lung cancer mutation delivers meaningful survival gains with manageable side effects and notably penetrates the brain, where this cancer often spreads.
This large Italian real-world registry (n=119 EGFRex20ins NSCLC) confirms that amivantamab delivers clinically meaningful outcomes — ORR 37.5%, mOS 16.9 months — with a manageable safety profile consistent with the pivotal CHRYSALIS trial. The intracranial activity signal (icPFS 11.6 months) is particularly notable as brain metastases are common in this population and historically difficult to treat.
What the study was
- Study design
- Multicenter retrospective observational study (real-world registry)
- Population
- Advanced NSCLC patients with EGFR exon 20 insertion mutations enrolled in Italian ATLAS real-world registry (Jan–Dec 2024)
- Sample size
- 119
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cancer
Why it surfaced
Real-world validation of amivantamab — a recently approved bispecific EGFR-MET antibody — in EGFRex20ins NSCLC; largest Italian registry dataset confirming CHRYSALIS efficacy in routine practice with notable intracranial activity; pipeline_priority HIGH via NOVEL_TREATMENT flag.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.